CLAIM CARD
Within-corpus tensions emerge when comparing findings across study designs and populations. Similarly, the robust anti-inflammatory effects observed in fatty liver (Ge 2023) and autoimmune myocarditis (Zhuang 2025) models do not directly translate to the older adult population tested in the phase 2b/3 trial (Targeting 2021). The mechanistic convergence identified between rapamycin and other compounds on MAPK pathways (Wink 2022) provides a potential reconciliation framework, suggesting that dose, tissue context, and disease state may determine whether mTOR inhibition yields anti-inflammatory benefits. These observations collectively indicate that rapamycin's immune-modulatory profile is context-dependent, with positive preclinical and observational signals coexisting with mixed human trial evidence.
Evidence grade: exploratory
Contradiction status: none
Publication: f02d4a53-03e5-47ed-9876-75a416e3bd24
Provenance: Derivation Web chain
Citation Support
source_1Moel 2025source_2Gkioni 2025source_3Smiaek 2023source_4Willows 2023source_5Harinath 2025